BBSRC Portfolio Analyser
Award details
Validation of the Vps34 PI 3-kinase as a new potential drug target in insulin sensitization
Reference
BB/M013278/1
Principal Investigator / Supervisor
Professor Bart Vanhaesebroeck
Co-Investigators /
Co-Supervisors
Dr Richard Angell
,
Professor Robert Semple
Institution
University College London
Department
Oncology
Funding type
Research
Value (£)
123,216
Status
Completed
Type
Research Grant
Start date
01/03/2016
End date
28/02/2017
Duration
12 months
Abstract
unavailable
Summary
This proposal aims to test the hypothesis that the Vps34 enzyme plays a role in metabolism. In our previous studies, using genetic approaches in the mouse and funded by the BBSRC, we have discovered that partial inactivation of Vps34 leads to improved glucose-tolerance and protection against the negative effects of a high fat diet. This suggests that Vps34 inhibitors could be useful in diseases such as diabetes. We now propose to test whether newly developed chemical blockers of Vps34 can induce the same effects as genetic inactivation of Vps34, in cell- and mouse-based models. This is a proof-of-concept project which, if the outcome is positive, can lay the foundations for Vps34 drug development and a translational programme of work.
Committee
Not funded via Committee
Research Topics
Pharmaceuticals
Research Priority
X – Research Priority information not available
Research Initiative
Follow-On Fund (FOF) [2004-2015]
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search